Pfizer
Search results
Lilly unites caring with discovery to create medicines that make life better for people around the world.
Lilly Canada is the Canadian affiliate of Eli Lilly and Company, one of the world’s largest research-based pharmaceutical companies. Our affiliate was founded in 1938 as a result of a collaboration between Eli Lilly and Company and Banting and Best, which produced the world’s first commercially available insulin.
For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs. On this page you will find Product Monographs and Patient Medication Information (also known as Consumer Information). You will also find instructions on how to use our devices.
Jan 27, 2022 · TORONTO, Jan. 27, 2022 /CNW/ - Lilly Canada is pleased to announce that Health Canada has authorized Verzenio ® (abemaciclib) (tablets), in combination with endocrine therapy, for the...
Established via a research collaboration with scientists at the University of Toronto, Eli Lilly Canada produced the world’s first commercially available insulin in partnership with the University of Toronto.
PP-MG-CA-0138 06/2024 | © Eli Lilly Canada Inc. 2024. All rights reserved. All rights reserved. Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.
Nov 22, 2020 · Canada has granted interim authorization to Eli Lilly's antibody drug for treating COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or...
If you need information about a Lilly medicine or want to report an adverse event or product quality complaint, please call Lilly Canada's Customer Response Centre at: 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Eli Lilly Canada (“Lilly Canada”) is the Canadian affiliate of Eli Lilly and Company, one of the world’s largest research-based pharmaceutical companies. Our affiliate was founded in 1938...
Feb 25, 2021 · The first and only anti-CGRP treatment with dual indications. TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. ( Lilly Canada) is pleased to announce that Emgality® (galcanezumab)...
